GLP-1 receptor agonists demonstrate significant anti-inflammatory properties beyond their established weight loss and glycemic control effects. The medications reduce circulating inflammatory markers and modulate immune cell activity across multiple preclinical and clinical studies, with documented benefits in metabolic syndrome, polycystic ovary syndrome, and inflammatory skin conditions. This anti-inflammatory profile represents a paradigm shift in understanding GLP-1 agonists as metabolic modulators rather than simple appetite suppressants. The chronic inflammation reduction could prove transformative for surgical outcomes, as persistent low-grade inflammation significantly impairs wound healing and increases complication rates. However, the clinical evidence remains preliminary—this review identifies a critical research gap regarding direct surgical outcomes in patients using these medications. The timing matters: GLP-1 agonists appear to influence chronic disease states rather than acute healing responses, suggesting their benefits accrue over months of treatment rather than immediate perioperative periods. As these drugs become ubiquitous in clinical practice, understanding their broader immunomodulatory effects becomes essential for optimizing patient care beyond their primary metabolic indications.